Burak Cem – VP & General Manager, Novo Nordisk Turkey
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Address: Nispetiye Caddesi, Akmerkez, E3 Blok, Kat:7 Etiler, Istanbul, Turkey 34335, Turkey
Tel: +90 212 3854040
Web: http://www.novoturk.com/documents/home_page/document/index.asp
Novo Nordisk is a global healthcare company with 89 years of innovation and leadership in diabetes care. The company also has leading positions within haemophilia care, growth hormone therapy and hormone replacement therapy.
Headquartered in Denmark, Novo Nordisk employs approximately 33,300 employees in 75 countries, and markets its products in 190 countries.
Novo Nordisk’s B shares are listed on NASDAQ OMX Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO).
Providing solutions mainly in Diabetes and Haemophilia
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Novo Nordisk Turkey has taken a degree of leadership by working to facilitate and encourage cooperation and collaboration between different stakeholders in the diabetes management ecosystem. For general manager Şebnem…
Would you like to provide our international readers with a brief introduction into Novo Nordisk’s Turkish affiliate? As you may know, Novo Nordisk has a rich history of over 85…
Evren Özlü, General Manager of Turkey and Sub-Saharan Africa at Boehringer Ingelheim, discusses the company’s double-digit growth in the last year, and its leading position as one of the fastest…
Polifarma is a Turkish pharma company dedicated to the hospital sector and biosimilars. Its chairman, Ufuk Kumrulu, explains how the company has managed to become a top two company in…
Drawing on over a dozen interviews with C-level pharmaceutical industry executives in Turkey, PharmaBoardroom has compiled a strategic overview of Turkey’s pharma talent potential, including what local talent can offer…
The president of the Investment Office of the Presidency of the Republic of Turkey, Burak Dağlıoğlu, outlines the country’s current economic situation after posting the second-highest GDP growth among G20…
Muzaffer Bal, CEO of Ali Raif, a Turkish generics firm, highlights the company’s new investment in a manufacturing plant, their refusal to follow the trend of Turkish local companies investing…
Süha Taşpolatoğlu, CEO of Abdi Ibrahim, Turkish pharma’s “national champion”, discusses the company’s ambitious bet on biosimilars, their position as the licensing and CMO partner of choice for multinational companies…
Ilko Pharmaceuticals is a family-owned Turkish generics and biosimilars company. General Manager Hatice Öncel explains the company’s investment in biosimilars in collaboration with South Korea’s Genexine and how recent success…
Dr Hamdi Akan, head of Turkey’s Clinical Research Association, dives into the country’s opportunities and barriers to become a clinical trials hub, including the world-class infrastructure and the need for…
İsmail Yormaz, Recordati’s VP and regional director for south-east, highlights how the Milan-based company has become a shining example of a successful localization strategy, upcoming launches and investments, as well…
Almost two decades after initiating large-scale health system reforms, Turkey has consolidated the provision of universal healthcare coverage to over 95 percent of the population. The effort, part of the…
Takeda’s general manager for Turkey, Şeyda Atadan Memiş, reflects on the Japanese giant’s ambitions in Turkey at a pivotal moment when the Shire integration has been completed. Atadan discusses how…
TITCK is the regulatory agency in charge of ensuring the safety of medicines, health products, cosmetics, and personal care products in Turkey. Its recently appointed president, Dr Tolga Karakan, discusses…
See our Cookie Privacy Policy Here